Lamzede(velmanase alfa)
Lamzede (velmanase alfa) is an enzyme pharmaceutical. Velmanase alfa was first approved as Lamzede on 2018-03-23. It is used to treat alpha-mannosidosis in the USA. It has been approved in Europe to treat alpha-mannosidosis.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Lamzede
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Velmanase alfa
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Lamzede | velmanase alfa-tycv | Chiesi Farmaceutici | N-761278 RX | 2023-02-16 | 1 products |
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| alpha-mannosidosis | — | D008363 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
velmanase alfa, Lamzede, Chiesi Farmaceutici S.p.A. | |||
| 2030-02-16 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alpha-mannosidosis | D008363 | — | — | 1 | 3 | 5 | — | 2 | 11 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Velmanase alfa |
| INN | velmanase alfa |
| Description | Velmanase alfa, sold under the brand name Lamzede, is a medication used for the treatment of alpha-mannosidosis. Velmanase alfa is a recombinant human lysosomal alpha-mannosidase.
|
| Classification | Enzyme |
| Drug class | enzymes |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298010 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB12374 |
| UNII ID | M91TG242P2 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 54 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use